Therapeutics of Corticosteroids in the Bovine Animal and Problems Surrounding Their Use W
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed. -
The Limited Role of Glucagon for Ketogenesis During Fasting Or in Response to SGLT2 Inhibition
882 Diabetes Volume 69, May 2020 The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition Megan E. Capozzi,1 Reilly W. Coch,1,2 Jepchumba Koech,1 Inna I. Astapova,1,2 Jacob B. Wait,1 Sara E. Encisco,1 Jonathan D. Douros,1 Kimberly El,1 Brian Finan,3 Kyle W. Sloop,4 Mark A. Herman,1,2,5 David A. D’Alessio,1,2 and Jonathan E. Campbell1,2,5 Diabetes 2020;69:882–892 | https://doi.org/10.2337/db19-1216 Glucagon is classically described as a counterregula- the oxidation of fatty acids, a shift in fuel utilization that tory hormone that plays an essential role in the pro- coordinates energy needs and glucose production (2). The tection against hypoglycemia. In addition to its role in actions of glucagon to increase lipid oxidation, including the regulation of glucose metabolism, glucagon has the production of ketone bodies that is a downstream end been described to promote ketosis in the fasted state. point of this process, have been defined by numerous – Sodium glucose cotransporter 2 inhibitors (SGLT2i) are experiments with cultured hepatocytes (3–5). Moreover, a new class of glucose-lowering drugs that act primarily the classic studies of Gerich et al. (6), using somatostatin to in the kidney, but some reports have described direct reduce circulating glucagon and mitigate diabetic ketoaci- effects of SGLT2i on a-cells to stimulate glucagon se- dosis (DKA), add to the now ingrained belief that glucagon cretion. Interestingly, SGLT2 inhibition also results in increased endogenous glucose production and ketone has both glucogenic and ketogenic activities. -
Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid. -
Utah Medicaid Pharmacy and Therapeutics Committee Drug
Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Single Ingredient Nasal Corticosteroids Beclomethasone dipropionate (Qnasl) Beclomethasone dipropionate monohydrate (Beconase AQ) Budesonide (Rhinocort) Ciclesonide (Omnaris, Zetonna) Flunisolide (Generic) Fluticasone Furoate (Flonase Sensimist) Fluticasone Propionate (Flonase, Xhance) Mometasone Furoate (Nasonex) Triamcinolone Acetonide (Nasacort) AHFS Classification: 52.08.08 Corticosteroids (EENT) Final Report February 2018 Review prepared by: Valerie Gonzales, Pharm.D., Clinical Pharmacist Elena Martinez Alonso, B.Pharm., MSc MTSI, Medical Writer Vicki Frydrych, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor Joanne LaFleur, Pharm.D., MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved Contents Abbreviations ................................................................................................................................................ 2 Executive Summary ....................................................................................................................................... 3 Introduction .................................................................................................................................................. 5 Table 1. Nasal corticosteroid products ............................................................................................. -
Drug Class Review Nasal Corticosteroids
Drug Class Review Nasal Corticosteroids Final Report Update 1 June 2008 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Dana Selover, MD Tracy Dana, MLS Colleen Smith, PharmD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Marian McDonagh, PharmD, Principal Investigator, Drug Effectiveness Review Project Copyright © 2008 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 1 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION ..........................................................................................................................5 Scope and Key Questions .......................................................................................................................7 METHODS ....................................................................................................................................9 Literature Search .....................................................................................................................................9 -
Pharmacology/Therapeutics II Block III Lectures 2013-14
Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine -
Ketosis Diagnosis and Monitoring in High-Producing Dairy Cows
Review Invited Review: Ketosis Diagnosis and Monitoring in High-Producing Dairy Cows Mariana Alves Caipira Lei 1 and João Simões 2,* 1 Department of Zootechnics, School of Agricultural and Veterinary Sciences, University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal; [email protected] 2 Department of Veterinary Sciences, School of Agricultural and Veterinary Sciences, University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal * Correspondence: [email protected]; Tel.: +351-259-350-666 Abstract: This work reviews the current impact and manifestation of ketosis (hyperketonemia) in dairy cattle, emphasizing the practical use of laboratory methods, field tests, and milk data to monitoring this disease. Ketosis is a major issue in high-producing cows, easily reaching a prevalence of 20% during early postpartum when the negative energy balance is well established. Its economic losses, mainly related to decreasing milk yield, fertility, and treatment costs, have been estimated up to €250 per case of ketosis/year, which can double if associated diseases are considered. A deep relationship between subclinical or clinical ketosis and negative energy balance and related production diseases can be observed mainly in the first two months postpartum. Fourier transform infrared spectrometry methods gradually take place in laboratory routine to evaluates body ketones (e.g., beta-hydroxybutyrate) and probably will accurately substitute cowside blood and milk tests at a farm in avenir. Fat to protein ratio and urea in milk are largely evaluated each month in dairy farms indicating animals at risk of hyperketonemia. At preventive levels, other than periodical evaluation of body condition score and controlling modifiable or identifying non-modifiable risk Citation: Lei, M.A.C.; Simões, J. -
Effects of Ketone Bodies on Brain Metabolism and Function In
International Journal of Molecular Sciences Review Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases Nicole Jacqueline Jensen 1,* , Helena Zander Wodschow 1, Malin Nilsson 1 and Jørgen Rungby 1,2 1 Department of Endocrinology, Bispebjerg University Hospital, 2400 Copenhagen, Denmark; [email protected] (H.Z.W.); malin.sofi[email protected] (M.N.); [email protected] (J.R.) 2 Copenhagen Center for Translational Research, Copenhagen University Hospital, Bispebjerg and Frederiksberg, 2400 Copenhagen, Denmark * Correspondence: [email protected] Received: 4 November 2020; Accepted: 18 November 2020; Published: 20 November 2020 Abstract: Under normal physiological conditions the brain primarily utilizes glucose for ATP generation. However, in situations where glucose is sparse, e.g., during prolonged fasting, ketone bodies become an important energy source for the brain. The brain’s utilization of ketones seems to depend mainly on the concentration in the blood, thus many dietary approaches such as ketogenic diets, ingestion of ketogenic medium-chain fatty acids or exogenous ketones, facilitate significant changes in the brain’s metabolism. Therefore, these approaches may ameliorate the energy crisis in neurodegenerative diseases, which are characterized by a deterioration of the brain’s glucose metabolism, providing a therapeutic advantage in these diseases. Most clinical studies examining the neuroprotective role of ketone bodies have been conducted in patients with Alzheimer’s disease, where brain imaging studies support the notion of enhancing brain energy metabolism with ketones. Likewise, a few studies show modest functional improvements in patients with Parkinson’s disease and cognitive benefits in patients with—or at risk of—Alzheimer’s disease after ketogenic interventions. -
Gluconeogenesis and Bovine Ketosis
October, 1968] NUTRITION REVIEWS 313 cattle at the time of slaughter showed no other two stations, but the differences effect of rearing practice on protein, iron, were insignificant. For some reason, the thiamine, riboflavin, or nicotinic acid vitamin A supplement added to the content. The fat content of this muscle concentrate was not very stable. As a increased with the higher level of con- result, vitamin A was low in the livers, centrates and restricted rearing area. With especially at two of the stations. However, Downloaded from https://academic.oup.com/nutritionreviews/article/26/10/313/1832143 by guest on 27 September 2021 this went a reduction in the moisture the method of rearing had no effect on content. The most outstanding observation this level. This was also true of the pro- was that the thiamine content of this mus- tein, iron, thiamine, riboflavin, niacin, cle of the animals at one station, at which pyridoxine, vitamin BIZ. and folic acid the most intensive feeding method was concentrations in the liver. studied, was almost twice that of the ani- Results of these studies indicate that mals at the other two stations. This was the method of rearing sheep and beef also true for the superficial digital flexer cattle has no significant effect on the muscle. There were, however, no such nutrient content of the same muscles or differences for any of the other nutrients studied. of the livers. There are inherent differences Livers from the animals at the station in the amounts of certain vitamins in dif- where the muscles had a high concentra- ferent muscles within the same animal tion of thiamine had slightly more thiamine and for the same muscle from different than livers of animals from either of the breeds. -
Metabolic Switching Is Impaired by Aging and Facilitated by Ketosis
bioRxiv preprint doi: https://doi.org/10.1101/2019.12.12.874297; this version posted December 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 Metabolic switching is impaired by aging and facilitated by 2 ketosis independent of glycogen 3 Abbi R. Hernandez1, Leah M. Truckenbrod1, Quinten P. Federico1, Keila T. Campos1, Brianna 4 M. Moon1, Nedi Ferekides1, Meagan Hoppe1, Dominic D’Agostino3, 4, Sara N. Burke1, 2* 5 1Department of Neuroscience, University of Florida, Gainesville, FL, USA; 2Intitute on Aging, 6 University of Florida, Gainesville, FL, USA; 3Department of Molecular Pharmacology and 7 Physiology, University of South Florida, Tampa, FL, USA; 4Institute for Human and Machine 8 Cognition, Ocala, FL, USA 9 *Corresponding Author 10 [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2019.12.12.874297; this version posted December 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 11 ABSTRACT 12 The ability to switch between glycolysis and ketosis promotes survival by enabling 13 metabolism through fat oxidation during periods of fasting. Carbohydrate restriction or stress can 14 also elicit metabolic switching. Keto-adapting from glycolysis is delayed in aged rats, but factors 15 mediating this age-related impairment have not been identified. -
Medical and Therapeutic Applications of Ketosis
Review Article iMedPub Journals Health Science Journal 2020 www.imedpub.com ISSN 1791-809X Vol. 14 No. 1: 690 DOI: 10.36648/1791-809X.14.1.690 Medical and Therapeutic Applications of Michael Paden Smith* Ketosis: An Overview F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, USA Abstract Ketosis is a metabolic state in which the body uses ketones as an alternative fuel *Corresponding author: source to glucose. When dietary carbohydrate intake is limited, the body turns Michael Paden Smith to ketones, produced initially by brief breakdown of muscles tissue and then by lipolysis of adipose tissue. Fasting is also a means of inducing a state of ketosis. [email protected] The ketogenic diet, a low-carbohydrate, high-fat diet, severely restricts carbohydrate intake and has been used to treat various health conditions, such F. Edward Hebert School of Medicine, as epilepsy, for over a century. Although the ketogenic diet is controversial, due Uniformed Services University of the Health to its strict dietary protocols, laboratory and clinical research suggest that there Sciences, USA. are many therapeutic benefits to be reaped through its implementation. Children with epilepsy have had their seizures reduced or completely controlled from Tel: 8088001789 maintaining a state of ketosis. Ketosis is also shown to help reduce tumor size in certain cancers. Additionally, certain types of athletic performance have been shown to be Citation: Smith MP (2020) Medical and enhanced through a low-carbohydrate, high-fat diet and body composition has Therapeutic Applications of Ketosis: An dramatically improved in clinical research of subjects on a ketogenic diet with Overview. -
Triamcinolone Acetonide Nasal Spray Metered
Contains Nonbinding Recommendations Draft Guidance on Triamcinolone Acetonide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Triamcinolone acetonide Dosage Form; Route: Spray, metered; nasal Strength: 0.055 mg/spray Recommended Studies: In vitro and in vivo studies FDA recommends the following in vitro and in vivo studies to establish bioequivalence (BE) of the test (T) and reference (R) nasal sprays containing triamcinolone acetonide. In Vitro BE Studies FDA recommends that prospective applicants conduct the following in vitro BE studies on samples from each of three or more batches of the T product and three or more batches of the R product, with no fewer than 10 units from each batch. FDA recommends that three primary stability batches be also used to demonstrate in vitro BE. The three batches of the T product should be manufactured from, at minimum, three different batches of the drug substance, three different batches of critical excipients, and three different batches of the device components (e.g., pump and actuator) proposed for the final device configuration of the commercial product. The T product should consist of the final device constituent part and final drug constituent formulation intended to be marketed. The following in vitro BE tests are recommended: 1.